KP1077
Idiopathic Hypersomnia / Sleep Disorders
Phase 2In pipeline (acquired from Acer)
Key Facts
Indication
Idiopathic Hypersomnia / Sleep Disorders
Phase
Phase 2
Status
In pipeline (acquired from Acer)
Company
About Zevra Therapeutics
Zevra Therapeutics is a purpose-driven rare disease company with a dual focus on commercial execution and late-stage clinical development. Its strategy involves following scientific data to build compelling regulatory narratives that address significant unmet patient needs. With a seasoned leadership team and a pipeline anchored in rare neurological and genetic disorders, Zevra aims to become a leader in the orphan drug space by advancing transformative therapies.
View full company profile